×
Merus Share Holder Equity 2016-2025 | MRUS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merus share holder equity from 2016 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
View More
Merus Share Holder Equity 2016-2025 | MRUS
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Merus share holder equity from 2016 to 2025. Share holder equity can be defined as the sum of preferred and common equity items
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$222.8B
Amgen (AMGN)
$162B
Gilead Sciences (GILD)
$140.6B
Vertex Pharmaceuticals (VRTX)
$118.3B
Bristol Myers Squibb (BMY)
$96.7B
CSL (CSLLY)
$85.2B
GSK (GSK)
$76.5B
Regeneron Pharmaceuticals (REGN)
$60.3B
Alnylam Pharmaceuticals (ALNY)
$42.3B
Argenex SE (ARGX)
$36.4B
BioNTech SE (BNTX)
$27.1B
Royalty Pharma (RPRX)
$20.8B
Insmed (INSM)
$19.3B
Biogen (BIIB)
$18.9B
Illumina (ILMN)
$17.4B
Genmab (GNMSF)
$15.2B
Genmab (GMAB)
$14.8B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.1B
Exelixis (EXEL)
$12.1B
QIAGEN (QGEN)
$11.3B
BioMarin Pharmaceutical (BMRN)
$11.1B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10B
Bio-Techne Corp (TECH)
$9.2B
Exact Sciences (EXAS)
$9.1B
Verona Pharma American Depositary Share (VRNA)
$8.9B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.7B
Legend Biotech (LEGN)
$7.6B